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Stromal interaction essential for vascular endothelial growth factor
A-induced tumour growth via transforming growth factor-b
signalling
AC Weidenaar1, A ter Elst1, KR Kampen1, TGJ Meeuwsen-de Boer1, HJM de Jonge1, FJG Scherpen1,
WFA den Dunnen2, WA Kamps1 and ESJM de Bont*,1
1Division of Pediatric Oncology/Hematology, Department of Pediatrics, Beatrix Children’s Hospital, University Medical Center Groningen, University of
Groningen, PO Box 30.001, Groningen 9700 RB, The Netherlands; 2Division of Pathology, Department of Pathology and Medical Biology, University
Medical Center Groningen, University of Groningen, Groningen, The Netherlands
BACKGROUND: High vascular endothelial growth factor (VEGFA) levels at the time of diagnosis confer a worse prognosis to multiple
malignancies. Our aim was to investigate the role of VEGFA in promoting tumour growth through interaction with its environment.
METHODS: HL-60 cells were transduced with VEGFA165 or control vector using retroviral constructs. Control cells (n¼ 7) or
VEGFA165 cells (n¼ 7) were subcutaneously injected into NOD/SCID mice. Immunohistochemistry of markers for angiogenesis
(CD31) and cell proliferation (Ki67) and gene expression profiling of tumours were performed. Paracrine effects were investigated by
mouse-specific cytokine arrays.
RESULTS: In vivo we observed a twofold increase in tumour weight when VEGFA165 was overexpressed (P¼ 0.001), combined with
increased angiogenesis (P¼ 0.002) and enhanced tumour cell proliferation (P¼ 0.001). Gene expression profiling revealed human
genes involved in TGF-b signalling differentially expressed between both tumour groups, that is, TGFBR2 and SMAD5 were lower
expressed whereas the inhibitory SMAD7 was higher expressed with VEGFA165. An increased expression of mouse-derived
cytokines IFNG and interleukin 7 was found in VEGFA165 tumours, both described to induce SMAD7 expression.
CONCLUSION: These results suggest a role for VEGFA-driven tumour growth by TGF-b signalling inhibition via paracrine mechanisms
in vivo, and underscore the importance of stromal interaction in the VEGFA-induced phenotype.
British Journal of Cancer (2011) 105, 1856–1863. doi:10.1038/bjc.2011.460 www.bjcancer.com
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The level of vascular endothelial growth factor (VEGFA) at time of
diagnosis is an independent prognostic factor for treatment
outcome in multiple malignancies, including (paediatric) acute
myeloid leukaemia (AML) (Aguayo et al, 1999; de Bont et al, 2002).
As a result, targeting VEGFA has been a subject of extensive
research during the last decades.
In general, tumour growth is supported by angiogenesis,
the formation of new blood vessels. An increase in microvessel
density (MVD) is seen in many malignancies. In AML, enhanced
bone marrow angiogenesis at diagnosis was shown, recovering
to normal levels when CR was achieved (Padro et al, 2000;
de Bont et al, 2001). Moreover, a correlation was found
between the degree of VEGFA expression and the increase
in bone marrow vascularisation at AML presentation (de Bont
et al, 2001).
Co-expression of VEGFA and its tyrosine kinase receptors
VEGFR1 and VEGFR2 has been reported previously in AML. Upon
binding of its ligand, both receptors can activate several down-
stream pathways such as PI3-kinase and MAPK signalling,
inducing cell proliferation and cell survival (Lewis et al, 1998;
Bellamy et al, 1999; Grandage et al, 2005). Apart from autocrine
effects, secreted VEGFA stimulates endothelial and stromal cells
that may drive leukaemic cell proliferation via paracrine effects
(Fiedler et al, 1997; Lee et al, 2007).
Although a role for VEGFA in malignant progression was
implicated, the exact mechanism by how increased VEGFA levels
influence tumour growth is still not completely understood. In this
study a model was generated to investigate the effect of VEGFA in
tumour progression. Using a human AML cell line transduced with
VEGFA165 or empty vector (negative control), we were able to show
that in vitro overexpression of VEGFA165 did not influence cell
growth patterns and drug resistance, whereas in vivo VEGFA165
overexpression enhanced tumour outgrowth and induced the
expression of host-derived cytokines. Our study suggests that
VEGFA165-promoted tumour growth was mediated by a paracrine-
induced inhibition of the TGF-b signalling pathway, and underlines
the importance of targeting the tumour microenvironment.
MATERIALS AND METHODS
Cell line culture and transduction
The human AML cell line HL-60 was obtained from the ATCC
(Manassas, VA, USA) in 2006. Cells have last been tested and
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authenticated by flow-cytometry analysis in 2009. HL-60 cells were
cultured in RPMI-1640 medium supplemented with 1% penicillin/
streptomycin and 10% fetal bovine serum (Hyclone, Logan, UT,
USA). Retroviral supernatants were generated by cotransfection of
2 mg reporter constructs pMSCV-iGFP-VEGFA165 or pMSCV-iGFP
(empty vector, negative control) and 2 mg packaging plasmid
pCLampho into 293T cells using FuGENE HD transfection reagent
(Roche, Almere, the Netherlands). HL-60 cells (5 104) were
incubated with retroviral supernatants, which were filtered
through 0.45-mm pore size syringe-mounted filters. Incubation
was supplemented with 8 mgml1 polybrene. This procedure was
repeated for 2 consecutive days after which stably transduced cells
were expanded. Transduction efficiency was measured by FACS
analysis, which demonstrated an efficiency of 25% for cells
transduced with the empty vector and 10% for cells transduced
with VEGFA165. Cells were sorted on a MoFlo (DAKO Cytomation,
AS, Glostrup, Denmark); after sorting the percentage of transduced
cells was 90% for the empty vector (control cells) and 67% for the
VEGFA165 vector (VEGFA165 cells). Cells were cultured overnight
under described serum conditions before use.
Animal study
NOD/SCID mice (kindly provided by Dr LD Shultz, The Jackson
Laboratory, Bar Harbor, ME, USA) were bred and maintained at the
Central Animal Facility, University of Groningen, Groningen, the
Netherlands. Animals were kept under laminar flow conditions
during the experiment. Our model was generated by subcutaneously
injecting 10 106 VEGFA165 cells (VEGFA165 tumour) or control
cells (control tumour) into the right flank of sublethally irradiated
(2Gy) 6–8-week-old NOD/SCID mice (n¼ 14). Mice were monitored
for 15 days, during which tumour growth was assessed periodically.
Tumour volumes were determined by external measurement
according to the equation (V¼ LW2) 0.5, where V¼ volume,
L¼ length and W¼width (Tsujii et al, 1998). Mice were killed using
cervical dislocation at day 15 and tumours were harvested. Tumours
were split and either snap-frozen or fixed in formalin and embedded
in paraffin for immunohistochemistry or other analyses. All
procedures involving animals were performed in accordance with
local ethical animal laws and policies.
RNA extraction and real-time PCR
Total RNA from frozen tumour material was extracted with
NucleoSpin RNA II kit according to the manufacturer’s protocol
(Macherey-Nagel, Duren, Germany). Complementary DNA was
prepared at 371C for at least 1 h in 20 ml reaction mixture
containing 2 mg of total RNA, random hexamers (Pfizer, Capelle
a/d IJssel, the Netherlands), 5 first strand buffer, RNAsin
and reverse transcriptase (Gibco BRL, Grand Island, NY, USA).
Real-time PCR was performed using iQ SYBR green supermix
(Bio-Rad, Hercules, CA, USA). All PCR reactions and data analysis
were performed on the iCycler iQ Real-Time Detection System
(Bio-Rad). Expression of genes of interest was standardised for
expression of hRPL22 or mb-actin (arbitrary units, AU). Human-
specific (h) and mouse-specific (m) primers for the reverse
transcriptase PCR are listed in Supplementary Table S1. The
primers were checked in NCBI blasts and did not occur in mouse
genome or transcriptome. In addition, no PCR product could be
detected in mouse tissue with these primers.
ELISA and functional assay of VEGFA
Secretion of VEGFA was detected in the supernatant using commer-
cially available ELISAs (Quantikine immunoassays, R&D Systems,
Abingdon, UK) following the manufacturer’s instructions. The
functionality of secreted VEGFA from transduced cells was detected
by adding its supernatant to endothelial cells and quantify expression
of VEGFA-specific genes EGR3, NUR77 and NOR1 in endothelial cells
with real-time PCR, described in detail by Liu et al (2003).
Flow cytometry analysis
For BrdU incorporation, a measure of DNA-synthesis, 0.5 106
cells were incubated for 2, 4 or 8 h with 0% or 10% fetal calf serum
in presence of 1 mM demecolcine (Sigma, St Louis, MO, USA) and
10 mM BrdU (BD, Alphen a/d Rijn, the Netherlands), and prepared
according to the BdrU-assay protocol following the manufacturer’s
instructions (BD); cells were neutralised for acids in 0.5M
EDTA, secondary antibody: phycoerythrin-conjugated anti-mouse
(DAKO, AS, Glostrup, Denmark). Measurements with FACScalibur
LSR-II (BD), data were analysed using FlowJo.
Cellular drug resistance measurement using total cell kill
assay
A total cell kill assay was performed on VEGFA165 cells and
control cells using Amsacrine (0.05–2 mgml1) in different
concentrations in quadruplicate following former publications
(Weidenaar et al, 2008). Optical density in the total cell kill assay is
linearly related to the number of viable cells.
Microarray analysis
RNA from 14 tumour samples was analysed using Affymetrix
Human Genome U133 Plus 2.0 GeneChip (Affymetrix, Santa Clara,
CA, USA). RNA quality control, cDNA labelling, microarray
hybridisation, scanning, data extraction and data normalisation
were performed by ServiceXS, Leiden, the Netherlands. Differen-
tially expressed genes were identified for tumours using multi-
variate permutation test in Biometric Research Branch ArrayTools
(BRB ArrayTools). BRB ArrayTools has been developed by the
Biometric Research Branch of the US National Cancer Institute
(http://linus.nci.nih.gov/BRB-ArrayTools.html). A total of 1000
permutations were completed to identify the list of probe sets.
Differentially expressed probe sets were identified using a two-
sample t-test, threshold Po0.001 and false discovery rate (FDR) of
o0.25 was used. Gene ontology (GO) categories and KEGG pathways
were determined using DAVID (Database for Annotation, Visualiza-
tion and Integrated Discovery, Bioinformatics Resources 6.7, National
Institute of Allergy and Infectious Diseases (NIAID), NIH, http://
david.abcc.ncifcrf.gov/knowledgebase). Probe sets with a significance
level of 0.001 and FDR o0.25 were used for GO analysis. Gene set
expression comparisons were performed with univariate two sample
t-test at a significance level of Po0.05, followed by 200 permutations.
Affymetrix array results were validated using quantitative (Q)RT-PCR
with human-specific primers for 11 genes of interest (Supplementary
Figure S1).
Immunohistochemical analysis for vessel density and
proliferation
Frozen tumour samples were cut into 4-mm sections and studied
for vessel density by staining with CD31 (platelet endothelial cell
adhesion molecule (PECAM)-1) as well as for proliferation by
staining with Ki67. Sections were blocked for endogene peroxidase
with 0.25% H2O2 and incubated with mouse-specific CD31 (BD).
Subsequently, sections were incubated with secondary antibody
(swine) anti-rat biotin (DAKO), amplified with (biotin) streptavi-
din ABComplex/HRPO (DAKO) and detected by 3-amino-9-
ethylcarbazole (Sigma). After that slides were coloured with
haematoxylin. Negative controls were produced using non-specific
IgG as primary antibody. Sections for Ki67 were treated similarly
except for the antibodies: primary monoclonal mouse anti-human
Ki67 antibody (DAKO) and secondary antibody (rabbit) anti-
mouse biotin (DAKO). Vessel density was assessed using light
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microscopy at  50 magnification in areas of the slide containing
the highest numbers of microvessels representing most intense
microvasculature (hotspots). After the hotspots were identified,
total number of vessels per selected image was counted at  400
magnification. At least four hotspots were counted for each
section. Proliferation was evaluated by the percentage of Ki67
positive tumour cells in four hotspot areas (selected at  50
magnification): the selected image was divided into four areas, and
the percentage of Ki67-positive tumour cells was estimated for all
four areas at  400 magnification. The mean of the four estimates
was considered the count of that hotspot. Stainings were evaluated
by two investigators who had no knowledge of tumour character-
istics. Variability between investigators for vessel count was
r¼ 0.993 and for proliferation count was r¼ 0.996. The mean of
the two independent counts was considered to be the final
measurement for each counting field and hotspot.
Cytokine array
In VEGFA165 (n¼ 4) and control (n¼ 4) tumours 40 mouse-
specific cytokine levels were determined by using proteome
profiler mouse cytokine array panel A kit (R&D Systems)
according to manufacturer’s instructions (400 mg protein of each
sample was added). Spot densities were quantified with Scanalyze
software (http://rana.lbl.gov/EisenSoftware.htm) and exported to
Microsoft Excel. Spot densities were corrected for individual
background to diminish interarray variances. To assess the mouse
specificity of the cytokine array, protein extracts of the human
HL-60 cell line and of the mouse MS5 cell line were applied to the
cytokine array. As expected, a strong signal was found for the MS5
mouse cells, and no signal could be detected for the HL-60 control
cells (Supplementary Figure S2).
Statistical analysis
Wilcoxon signed-rank test was used to compare the growth of both
cell lines. Tumour volumes between VEGFA165 tumours and
control tumours were determined using the Student’s t-test.
Differences between tumour volumes at indicated time points
were calculated using the Student’s paired t-test. Correlation
between expression of VEGFA165, tumour volume, tumour weight,
percentage of cell proliferation and MVD were calculated using
Spearman’s correlation. Mann–Whitney U-test was used for
comparison of vessel and proliferation counts, QRT-PCR as well
as mouse-specific cytokines differentially expressed within VEG-
FA165 tumours and control tumours. Po0.05 was considered
significant.
RESULTS
Functional VEGFA165 overexpression in HL-60 cells
We transduced HL-60 cells with VEGFA165 (retroviral vectors
schematically depicted in Figure 1A). VEGFA165 mRNA expres-
sion and secreted protein levels were 3–4-fold upregulated in
VEGFA165 cells compared with control cells (Figure 1B and C). To
test the functionality of the produced VEGFA165, conditioned
medium of VEGFA165-transduced cells or control cells was added
to endothelial cells (HUVECs) and the mRNA expression of a
VEGFA responsive gene EGR3 was measured. A fivefold upregula-
tion of EGR3 was detected in HUVEC cells after incubation with
conditioned medium of VEGFA165-transduced cells compared
with conditioned medium of control cells (Figure 1D). FACS
analysis showed KDR expression in VEGFA165-transduced cells
similar to control cells. In vitro cell proliferation and cell growth
was similar in both cell lines (Figures 1E and F) and no difference
in drug resistance was observed between VEGFA165 cells and
control cells (data not shown).
Overexpression of VEGFA165 results in increased
angiogenesis and cell proliferation in a s.c. xenograft
mouse model
To investigate the role of VEGFA165 overexpression in vivo, we
subcutaneously inoculated VEGFA165 cells or control cells in
mice. Tumour volume of VEGFA165 tumours increased more
rapidly than control tumours, with a significant difference at day
13 and 15 (Po0.05 and Po0.01 respectively, Figure 2A). When
tumour-bearing mice were killed at day 15 tumour weight of
VEGFA165 tumours (median weight 995mg, range 670–1344) was
significantly (P¼ 0.001) increased compared with the control
tumours (median weight 464mg, range 413–646) (Figure 2B).
MVD in VEGFA165 tumours (median MVD 64.9 vessels per hpf,
range 54.4–88.6) was significantly (P¼ 0.002) enhanced compared
with control tumours (median MVD 46.1 vessels per hpf, range
39.9–56.5), and a significant (P¼ 0.001) increase in tumour cell
proliferation fraction in VEGFA165 tumours was found (median:
76.3%, range 66.3–91.6) compared with control tumours (median:
50.3%, range 35.4–65.6) (Figure 2C–H). Interestingly, tumour
weight was significantly correlated to MVD (r¼ 0.566, P¼ 0.044)
and percentage of proliferating cells (r¼ 0.722, P¼ 0.004). In
contrast to in vitro results, in vivo a clear phenotype could be
appreciated as increased angiogenesis and tumour cell prolifera-
tion was evident.
Distinct gene expression profiles related to VEGFA165
overexpression in vivo
To obtain a more detailed understanding of the phenotype within
the tumour cells overexpressing VEGFA165, mRNA of VEGFA165
tumours and control tumours was isolated, amplified and
hybridised to Affymetrix human U133 Plus 2.0 GeneChips. Class
comparison analysis revealed 761 probe sets to be differentially
expressed between the two tumour groups; 242 probe sets were
higher expressed in VEGFA165 tumours whereas 519 probe sets
were lower expressed in these tumours (complete list shown in
Supplementary Table S2). As expected, VEGFA was significantly
higher expressed in the VEGFA165 tumours compared with
control tumours (Po1 105).
Subsequently, GO analysis of the upregulated probe sets in
VEGFA165 tumours revealed enrichment for the process of
‘angiogenesis’ (GO:0001525, P¼ 0.03) in accordance with the
immunohistochemical staining for MVD. The GO term ‘cell death’
(GO: 0008219, P¼ 0.02) was enriched in the downregulated probe
sets of the VEGFA165 tumours, underscoring the observed
increase in tumour growth and cell proliferation (complete list
shown in Supplementary Table S3).
The list of up and downregulated genes in VEGFA165 tumours
include known genes involved in neoplasia (e.g. S100A8 involved
in leukaemia; S100A9 in prostate carcinoma; BCL9, CCND1 and
CTNNB1) (Hermani et al, 2006; Mani et al, 2009; Nicolas et al,
2011; Siapati et al, 2011). In addition, the cytokine receptors IL4R
and IL7R were found to be higher expressed in VEGFA165
tumours implicating the possibility of paracrine effects.
Notable, genes involved in TGF-b signalling (SOS1, SOS2,
SMAD5, LTBP3, TGFBR2, IRF7 and CREBZF) were found to be
significantly (Po0.01) downregulated in the VEGFA165 tumours.
In addition, SMAD7, a negative modulator of TGF-b signalling,
was found to be upregulated in VEGFA165 tumours. Three other
genes involved in the TGF-b signalling pathway were also found to
be significantly (Po0.05) differentially expressed (SMAD3, IRF7,
SMURF2).
To validate these results QRT-PCR with human-specific primers
was performed for 11 genes of interest (hVEGFA, hCREBZF,
hLTBP3, hIL4R, hIL7R, hSOS1, hSOS2, hSMAD3, hSMAD7,
hSMURF2 and hTGFBR2). Differential expression of these 11
genes could be confirmed using QRT-PCR (Supplementary
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Figure S1). Therefore, we conclude that the genes involved in the
TGF-b signalling pathway are derived from human cells within the
tumours.
Paracrine mechanisms have important roles in VEGFA165
tumours
We hypothesised that the in vivo growth benefit of high VEGFA165
levels occurs via interaction with its (micro)environment. In the
VEGFA165 tumours mouse-specific VEGFR2 mRNA was twofold
upregulated (P¼ 0.001, Supplementary Figure S1), the main
receptor for VEGFA signalling. Using mouse-specific cytokine
arrays (tested for mouse specificity, Supplementary Figure S2), we
assessed whether the increased tumour growth would be reflected
in altered mouse-derived cytokine expression. Five mouse-specific
cytokines were significantly (P¼ 0.03) higher expressed in
VEGFA165 tumours compared with control tumours: interleukin
5 (IL5), IL7, chemokine (C-X-C motif) ligand 9 (CXCL9, MIG),
colony-stimulating factor 1 (macrophage) (MCSF) and interferong
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Figure 1 Effect of VEGFA165 overexpression in vitro. (A) Schematic representation of the retroviral constructs that were used in this study. (B) Relative
mRNA expression of VEGFA165 in control cells compared with VEGFA165 cells. (C) Protein expression of VEGFA165 in control cells compared with
VEGFA165 cells: control cells 254.3 pgml1, VEGFA165 cells 1085.5 pgml1. (D) Functionality of the produced VEGFA by transduced cells. Recombinant
VEGFA induces the expression of EGR3 in ECs in a dose-dependent way (1 ngml1: 7.8 AU, 5 ngml1: 47.3 AU, 10 ngml1: 84.3 AU). Supernatant of
transduced cells contained functional VEGFA, indicated by the expression of EGR3. The VEGFA165 cells showed a higher expression of EGR3 than the
control cells, demonstrating that VEGFA165 cells produce more functional VEGFA (control cells: 22.0 AU; VEGFA165 cells: 106.5 AU). Similar graphs were
seen when investigating the expression of NUR77 and NOR1. (E) BdrU incorporation of control cells and VEGFA165 cells cultured in serum-free
conditions. After 2, 4 and 8 h cells were harvested and the percentage of cells that incorporated BrdU was analysed by flow cytometry. Percentage of BrdU-
incorporating cells: after 2 h 39% vs 44%; after 4 h 69% vs 60%; after 8 h 92% vs 89%. Background staining in the absence of BrdU wasB1%. Similar graphs
were seen when cells were cultured with 10% fetal calf serum. (F) No significant difference in cell growth of VEGFA165 cells compared with control cells
was seen when cells were cultured with 10% fetal calf serum (P¼ 0.169, Wilcoxon signed-rank test).
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was found to be significantly (P¼ 0.03) lower expressed in
VEGFA165 tumours compared with control tumours (Figure 3B).
Together these data show that stroma-derived (i.e. mouse-derived)
cytokines are regulated in tumours overexpressing VEGFA,
suggesting that VEGFA exerts its effect on tumour growth via a
paracrine loop.
DISCUSSION
In this study we demonstrated that VEGFA165 overexpression
significantly enhanced tumour progression in vivo, accompanied
by a higher percentage of proliferating tumour cells and increased
angiogenesis. We hypothesise that the enhanced tumour cell
proliferation is accompanied by inhibition of the TGF-b signalling
pathway in the (human) tumour cells via various stromal-derived
mouse cytokines such as IL7 and IFNG (Figure 4).
High VEGFA levels predict a poor prognosis in multiple
malignancies, including haematological malignancies. In our
study, in vitro induction of high VEGFA165 levels did not alter
the proliferative status of VEGFA165 cells compared with control
cells despite the fact that HL-60 cells express VEGFR2 and the
possibility of an autocrine loop has been described (Weidenaar
et al, 2008). In contrast, overexpression of VEGFA165 in vivo





































































































Figure 2 Effect of VEGFA165 overexpression in vivo. (A) Tumour volumes were assessed periodically. At day 13 and day 15 a significant difference was
seen. Values expressed are the means±s.e.m. of seven xenografts per group. *Po0.05, **Po0.01. (B) Tumour weight of tumours derived from VEGFA165
cells was significantly increased compared with tumour weight of control tumours at day 15 (P¼ 0.001). Median weight of VEGFA165 tumours: 995mg
(range 670–1344), control tumours: 464mg (range 413–646). (C) CD31 staining of a VEGFA165 tumour and (D) a control tumour. (E) VEGFA165
tumours showed a significantly (P¼ 0.002) higher MVD compared with the control tumours. Median MVD control tumours: 46.1 per field (range 39.9–
56.5); median MVD VEGFA165 tumours: 64.9 vessels per field (range 54.4–88.6). (F) Ki67 staining of a VEGFA165 tumour and (G) control tumour. (H) A
significantly (P¼ 0.001) higher percentage of proliferating cells was found in the VEGFA165 tumours compared with the control tumours. Median
percentage of proliferating cells control tumours: 50.3% (range 35.4–65.6); median percentage of proliferating cells VEGFA165 tumours: 76.3% (range
66.3–91.6). A representative photograph from each group is shown (original magnification  50, with inset  400 magnification).
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Our data show that tumours overexpressing VEGFA165 were
characterised by enhanced vessel outgrowth. An increase in MVD
is seen in many malignancies, including haematological
malignancies, with VEGFA as a key player (Carmeliet and Jain,
2000; Padro et al, 2000; de Bont et al, 2001). Vessels are known for























Figure 3 Expression of mouse-specific cytokines. Mouse-specific cytokines significantly (P¼ 0.03) differentially expressed between the VEGFA165
















































Figure 4 Proposed mechanism for VEGFA165 induced tumour growth. VEGFA production from the (human) tumour cells results in an increased fraction
of host-derived stromal and endothelial cells. These (mouse) host-derived supportive cells produce a variety of cytokines that act on the (human) tumour
cells. As a result, genes involved in the TGF-b signalling pathway are differentially expressed, inducing the inhibition of TGF-b signalling. This, in turn, results in
decreased cell cycle arrest, which may explain the increased growth of VEGFA overexpression in tumour. The colours represent higher expressed (green)
and lower expressed (red) genes or cytokines within the VEGFA165 tumours; stimulatory effect; indirect stimulatory effect; –| inhibitory effect;
- - > translocation.
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excretion of various endothelial-derived growth factors of potential
benefit for tumour cells (Fiedler et al, 1997; Dankbar et al, 2000). Our
results show that endothelial and/or stromal cells within the tumour
express higher levels of mouse-specific cytokines (MCSF, IFNG, IL5,
IL7 and CXCL9) in VEGFA165 tumours compared with control
tumours (Figure 4). From the literature it is known that exposure of
human endothelial cells to VEGFA resulted in an increased
production of cytokines, including MCSF (Fiedler et al, 1997; Bellamy
et al, 1999; Dankbar et al, 2000). These results suggest that the effect
of VEGFA165 is stromal dependent.
New is that within the human tumour cells genes involved in the
TGF-b signalling pathway were found to be differentially expressed
between VEGFA165 tumours and control tumours. The TGF-b
signalling pathway is a negative regulator of cell cycle progression,
resulting in a cell cycle arrest via transcription of TGF-b-
responsive genes. TGFBR2, SMAD3, SMAD5, SOS1 and SOS2 were
found to be lower expressed in VEGFA165 tumours compared with
control tumours. In addition SMAD7 was found to be higher
expressed in VEGFA165 tumours compared with control tumours.
SMAD7 inhibits TGF-b signalling by preventing the activation of
other SMADs (Kleeff et al, 1999). These results suggest that the
block in cell cycle progression is decreased via downregulation of
TGF-b-responsive genes, resulting in cell proliferation. This is in
line with our observation that VEGFA165 tumours showed an
increased fraction of proliferating cells.
As no proliferative advantage was seen for the VEGFA165 cells
in vitro we hypothesised that the TGF-b signalling pathway is a result
of the interaction with environment. Gene expression analysis
revealed that nearly all of the genes involved in the TGF-b signalling
pathway were not differentially expressed between the VEGFA165
HL-60 cell lines and control HL-60 cell lines. Thus, our results are in
concordance with the knowledge that stromal support is essential in
tumour growth in vivo (Ayala et al, 2009).
Alterations in the TGF-b signalling pathway are found in human
malignancies, including haematological malignancies (Elliott and
Blobe, 2005; Dong and Blobe, 2006). Proposed mechanisms for the
reduced TGF-b signalling include a decrease in TGFBR2 expres-
sion or an increase in SMAD7 expression (Kim et al, 1999; Kleeff
et al, 1999). In our study, tumours overexpressing VEGFA165
showed lower expression of TGFBR2 and higher expression of
SMAD7, suggesting a resistance to the TGF-b-induced cell cycle
arrest. The expression of SMAD7 can be regulated by various genes
and cytokines, for example, IFNG and IL7 (Ulloa et al, 1999; Huang
et al, 2002). Our data revealed that, in response to VEGFA
expression by the tumour cells, these host-derived cytokines were
upregulated. In addition, our microarray data showed that
(human) IL7R was upregulated in the VEGFA165 tumours.
Together, these data suggest that VEGFA165 induces the expres-
sion of host-derived growth factors and cytokines, which in turn
induces inhibition of the TGF-b signalling pathway (Figure 4).
In conclusion, we show that VEGFA165 significantly enhances
tumour growth and tumour angiogenesis. We demonstrated that
tumour-derived VEGFA resulted in enhanced tumour cell pro-
liferation possibly by a paracrine inhibition of TGF-b signalling
within the tumour. These results indicate that the microenviron-
ment is essential for VEGFA-induced tumour growth. Combining
conventional therapeutic strategies with drugs targeting the
tumour environment may be of benefit for tumour treatment.
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